ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) Stock Price, Forecast & Analysis
Europe - BIT:1ROG - CH0012032048 - Common Stock
1ROG.MI Key Statistics, Chart & Performance
The current stock price of 1ROG.MI is 288 EUR.
1ROG.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 11.42 | 211.49B | ||
| SAN.PA | SANOFI | 11.72 | 216.96B | ||
| MRK.DE | MERCK KGAA | 13.3 | 49.20B | ||
| UCB.BR | UCB SA | 35.51 | 44.35B | ||
| BAYN.DE | BAYER AG-REG | 5.42 | 26.68B | ||
| 1BAYN.MI | BAYER AG-REG | 5.29 | 26.03B | ||
| IPN.PA | IPSEN | 12.64 | 10.88B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 26.56 | 10.94B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 96.23 | 8.91B | ||
| VIRP.PA | VIRBAC SA | 20.36 | 2.96B | ||
| DMP.DE | DERMAPHARM HOLDING SE | 16.95 | 1.82B | ||
| MEDCL.PA | MEDINCELL SA | N/A | 993.00M |
Related stock screener links
About 1ROG.MI
Company Profile
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Company Info
ROCHE HOLDING AG-GENUSSCHEIN
Grenzacherstrasse 124
Basel BASEL-STADT CH
Employees: 103249
Phone: 41616881111
ROCHE HOLDING AG-GENUSSCHEIN / 1ROG.MI FAQ
Can you describe the business of ROCHE HOLDING AG-GENUSSCHEIN?
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Can you provide the latest stock price for ROCHE HOLDING AG-GENUSSCHEIN?
The current stock price of 1ROG.MI is 288 EUR. The price increased by 2.13% in the last trading session.
What is the dividend status of ROCHE HOLDING AG-GENUSSCHEIN?
ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) has a dividend yield of 3.71%. The yearly dividend amount is currently 10.88.
How is the ChartMill rating for ROCHE HOLDING AG-GENUSSCHEIN?
1ROG.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1ROG.MI.
What is the market capitalization of 1ROG stock?
ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) has a market capitalization of 233.06B EUR. This makes 1ROG.MI a Mega Cap stock.
1ROG.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1ROG.MI.
1ROG.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1ROG.MI. 1ROG.MI has an excellent profitability rating, but there are some minor concerns on its financial health.
1ROG.MI Financial Highlights
Over the last trailing twelve months 1ROG.MI reported a non-GAAP Earnings per Share(EPS) of 21.11. The EPS increased by 5.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.31% | ||
| ROA | 9.95% | ||
| ROE | 32.88% | ||
| Debt/Equity | 1.06 |
1ROG.MI Forecast & Estimates
For the next year, analysts expect an EPS growth of 6.05% and a revenue growth 2.45% for 1ROG.MI